These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 16820342)

  • 1. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
    Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
    Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of angiotensin II receptor blockade with valsartan on carotid arterial stiffness and hemodynamic alterations in patients with essential hypertension.
    Okura T; Watanabe S; Kurata M; Koresawa M; Irita J; Enomoto D; Jotoku M; Miyoshi K; Fukuoka T; Higaki J
    Clin Exp Hypertens; 2008 Jul; 30(5):415-22. PubMed ID: 18633763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
    Savoia C; Touyz RM; Volpe M; Schiffrin EL
    Hypertension; 2007 Feb; 49(2):341-6. PubMed ID: 17159079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of valsartan on left ventricular myocardial functions in hypertensive patients with left ventricular hypertrophy.
    Kucukler N; Kurt IH; Topaloglu C; Gurbuz S; Yalcin F
    J Cardiovasc Med (Hagerstown); 2012 Mar; 13(3):181-6. PubMed ID: 22306782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of ATII blockers and calcium channel blockers on renal vascular resistance in patients with essential hypertension.
    Delić-Brkljacić D; Galesić K; Ivanac G; Manola S; Pintarić H; Stambuk K; Gaćina P; Radeljić V
    Coll Antropol; 2009 Dec; 33(4):1129-38. PubMed ID: 20102058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade.
    Ogata C; Kamide K; Suzuki Y; Sasaki O; Kubota Y; Sato H; Takiuchi S; Horio T; Inenaga T; Kawano Y
    Clin Nephrol; 2005 Nov; 64(5):352-7. PubMed ID: 16312262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
    Plum J; Bünten B; Németh R; Grabensee B
    J Am Soc Nephrol; 1998 Dec; 9(12):2223-34. PubMed ID: 9848776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients.
    Uchida J; Machida Y; Iwai T; Iguchi T; Kamada Y; Naganuma T; Kumada N; Kim T; Kawashima H; Nakatani T
    J Nephrol; 2011; 24(4):515-21. PubMed ID: 21240871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
    Karalliedde J; Maltese G; Hill B; Viberti G; Gnudi L
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
    Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
    Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of valsartan on progression of kidney disease in Japanese hypertensive patients with advanced, predialysis, chronic kidney disease: Kanagawa Valsartan Trial (KVT).
    Yasuda T; Endoh M; Suzuki D; Yoshimura A; Ideura T; Tamura K; Kamata K; Toya Y; Umemura S; Kimura K;
    Hypertens Res; 2013 Mar; 36(3):240-6. PubMed ID: 23154591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppressive effects of valsartan on microalbuminuria and CRP in patients with metabolic syndrome (Val-Mets).
    Shishido T; Konta T; Nishiyama S; Miyashita T; Miyamoto T; Takasaki S; Nitobe J; Watanabe T; Takeishi Y; Kubota I
    Clin Exp Hypertens; 2011; 33(2):117-23. PubMed ID: 21269062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo- and microalbuminuria.
    Katayama K; Nomura S; Ishikawa H; Murata T; Koyabu S; Nakano T
    Kidney Int; 2006 Jul; 70(1):151-6. PubMed ID: 16710356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
    Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short term effects of valsartan on portal blood flow in cirrhotic patients.
    Yalniz M; Demir A; Arslan A; Cihangiroğlu M
    Turk J Gastroenterol; 2003 Mar; 14(1):18-25. PubMed ID: 14593533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
    Ay SA; Cakar M; Karaman M; Balta S; Demirkol S; Unlu M; Kurt O; Altun B; Akhan M; Arslan E; Koc B; Bulucu F
    Ren Fail; 2013; 35(3):357-60. PubMed ID: 23297711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrarenal and carotid hemodynamics in patients with essential hypertension.
    Okura T; Watanabe S; Miyoshi K; Fukuoka T; Higaki J
    Am J Hypertens; 2004 Mar; 17(3):240-4. PubMed ID: 15001198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
    Ohishi M; Takagi T; Ito N; Tatara Y; Hayashi N; Shiota A; Iwamoto Y; Katsuya T; Rakugi H; Ogihara T
    Hypertens Res; 2007 Dec; 30(12):1187-92. PubMed ID: 18344623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.